Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

https://gskpro-com-preprod-cf5.gdsgsk.com/en-us/products/nucala/about/,1000

hyperlink,10000

NUCALA is indicated for the add-on maintenance treatment of patients 12 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

prescribed biologic Indicated for severe eosinophilic asthma*–31,000 patients and counting1†

*Source: IQVIA - NPATM audit: 12 mo. TRX data ending 11/18 (All rights reserved).
December 2015 to November 2018 data sourced from IQVIA and GSK. Claims data based on total number of unique patients who had at least one claim for NUCALA in the United States. Not all patients remained on therapy. Individual results may vary.

prescribed biologic Indicated for severe eosinophilic asthma*–31,000 patients and counting1†

Choose NUCALA for:

Powerful Protection
From Exacerbations2‡

Powerful Reduction
in OCS Dose

Lasting Evidence4‖

 

Choose NUCALA for:

Powerful Protection
From Exacerbations2‡

Powerful Reduction
in OCS Dose

Lasting Evidence4‖

MENSA (Trial 2): 32-week study comparing NUCALA 100 mg to placebo, each added to SOC in 576 patients with severe eosinophilic asthma. Primary Endpoint Results: Frequency of exacerbations. NUCALA: 0.83/year, placebo: 1.74/year; P<0.001. Secondary Endpoint Results: Frequency of exacerbations requiring hospitalization and/or ED visit; NUCALA: 0.08/year; placebo: 0.20/year; P=0.02.

§SIRIUS (Trial 3): 24-week study comparing NUCALA 100 mg to placebo in 135 patients with severe eosinophilic asthma receiving prednisone 5-35 mg (or equivalent) per day and regular use of high-dose ICS and 1 other controller. Primary Endpoint Results: Percent reduction in daily OCS dose (Weeks 20 to 24) while maintaining asthma control vs placebo; P=0.008.

COLUMBA: 4.5-year open-label study assessing the safety, immunogenicity, and efficacy of NUCALA 100 mg added to asthma controller therapy in 347 patients with severe eosinophilic asthma.

REFERENCES:

  1. Data on file, GSK.
  2. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-1207.
  3. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189-1197.
  4. Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma [published online ahead of print, October 22, 2018]. J Allergy Clin Immunol. doi.org/10.1016/j.jaci.2018.09.033.